Sign up for important Repatha® updates


Considering Repatha®? Want to get in touch with a Rep? Need practice information? Sign up today to stay connected.

First Name

Enter first name

Last Name

Enter last name

Email

Enter email address

Zip Code

Enter zip code

I am a...

Select your title

Privacy Statement
By clicking "Submit," you agree to disclose your personal information to Amgen and to be contacted by Amgen and their agents in the future regarding products, services, and/or information related to Repatha®. For more information about Amgen's privacy practices, please visit www.amgen.com/privacy.


Submit

Thank you.


Okay

PATIENT STORIES

Real people, real results

Watch the impact Repatha® had on reducing LDL and MI risk for real patients with established CVD

Individual results may vary.


CATHY

2 kids, 6 grandkids
Former principal

Cathy’s LDL-C ranged from 100-120 at her diagnosis and even while she was taking a statin.

Watch video

5:35

CESAR

Married with 4 kids
Retired judge

Before being prescribed Repatha®, Cesar's LDL-C was 79 while taking a statin.

Watch video

5:38

DAN

Married with 2 kids
Certified Financial Planner

Dan’s LDL-C was very high before his heart attack, dropping dramatically after taking Repatha®.

Watch video

4:20

MARK

Married, veteran
Works for the Forest Service

Mark’s LDL-C was 220-225 at his first diagnosis, not dropping far enough after taking a statin.

Watch video

4:50

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52‐week trial and seven 12‐week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®‐treated and placebo‐treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®‐treated and placebo‐treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new‐onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.

Cathy

X

Cesar

X

Dan

X

Mark

X